ArticleDiscover oncology2025
Ten-year outcomes of IMRT with chemotherapy versus IMRT alone for stage II-IVa nasopharyngeal carcinoma: a retrospective study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles".Clinical and translational radiation oncology · 2025Article
- Clinical efficacy and influencing factors of intensity-modulated radiation therapy in the treatment of sinonasal cancer.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundConcurrent chemoradiotherapy (CCRT) remains the cornerstone of treatment for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, data on long-term survival, particularly 10-year outcomes, are limited.
methodsThis retrospective study evaluated the clinical efficacy and acute hematologic toxicity of intensity-modulated radiation therapy (IMRT) in 177 newly diagnosed patients with locoregionally moderate or advanced NPC. Patients were categorized into three groups: IMRT alone; CCRT-including subgroups receiving neoadjuvant chemotherapy (NC) + CCRT, CCRT alone, and NC + CCRT + adjuvant chemotherapy (AC); and non-CCRT-including NC + IMRT + AC, and IMRT + AC.
resultsThe median follow-up duration was 48.4 months (range, 3.0-178.9 months). Acute hematologic toxicities were generally mild, with 86.4% (153/177) of patients experiencing only grade 0-2 toxicity. The 10-year OS, PFS, LRFS, and DMFS rates were 66.6%, 75.3%, 91.9%, and 81.2%, respectively. OS differed significantly among the three treatment groups (P = 0.01). Both the CCRT and non-CCRT regimens were associated with improved 10-year OS compared to IMRT alone, with absolute increases of 29.4% and 26.1%, respectively (P = 0.01 for both comparisons).
conclusionsIn the era of IMRT, chemoradiotherapy was associated with manageable acute hematologic toxicity in patients with NPC. Distant metastasis, particularly in those with N3 disease, remained the predominant pattern of failure. Compared with IMRT alone, both CCRT (CCRT, NC + CCRT + AC, NC + CCRT) and non-CCRT (NC + IMRT + AC, IMRT + AC) demonstrated a potential survival benefit in newly diagnosed patients with locoregionally moderate or advanced NPC. These findings warrant further validation in prospective randomized clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.